Anethole/trans-Anethole / Casp3 Cancer Research Results

ANE, Anethole/trans-Anethole: Click to Expand ⟱
Features:

Anethole — Anethole is a naturally occurring aromatic phenylpropene and volatile essential-oil constituent best represented by trans-anethole, the dominant anise-like compound in anise, star anise, fennel, and related botanicals. It is formally a small-molecule natural product / flavoring-agent phytochemical rather than an approved oncology drug. Standard abbreviations include ANE, t-ANE, and tAT for trans-anethole. In cancer research it is best classified as a preclinical multi-pathway chemosensitizing phytochemical with stronger evidence for apoptosis, cell-cycle arrest, NF-κB/PI3K-AKT/STAT3 modulation, and context-dependent oxidative-stress effects than for direct clinical use.
-botanical sources can co-contain estragole, especially fennel/basil/tarragon-type materials. Estragole is a separate phenylpropene with stronger toxicology concern, so whole-herb or essential-oil entries should not be treated as pure anethole
anethole analogues eugenol and isoeugenol

Primary mechanisms (ranked):

  1. Induction of intrinsic apoptosis through mitochondrial membrane-potential disruption, Bax/Bcl-2-family shift, caspase-9/caspase-3 activation, and DNA-fragmentation phenotypes.
  2. Suppression of proliferative and survival signaling, especially PI3K/AKT, STAT3, NF-κB, AP-1, JNK, and MAPK-related inflammatory-survival axes.
  3. Cell-cycle arrest and anti-clonogenic effects in several cancer-cell models, including prostate, breast, oral, osteosarcoma, lung, and glioma models.
  4. Autophagy modulation, especially in oral-cancer models, where anethole has been reported to trigger autophagy alongside apoptosis.
  5. Oxidative-stress modulation, which is model-dependent: some cancer models show ROS increase and mitochondrial stress, while oral-cancer data report ROS decrease with increased GSH activity.
  6. Chemosensitization, most clearly preclinical synergy with cisplatin in oral-cancer cells.

Bioavailability / PK relevance: Anethole is lipophilic and orally absorbable, with human metabolic studies showing dose-dependent disposition and major urinary detoxication products such as 4-methoxyhippuric acid. Translation is constrained by rapid metabolism, flavor-level safety limits, and the fact that many anticancer experiments use concentrations unlikely to be achieved safely through dietary exposure.

In-vitro vs systemic exposure relevance: Most anticancer effects are concentration-driven and commonly occur in the tens to hundreds of micromolar range. These levels likely exceed normal dietary or flavoring exposure and should be treated as pharmacologic experimental exposure rather than food-use exposure.

Clinical evidence status: Preclinical. There is no established human oncology indication for anethole and no convincing registered cancer trial program for anethole as an anticancer therapy. Evidence is mainly cell-culture, limited animal xenograft, and combination/sensitization studies.

Anethole Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis ↑ Bax, ↑ caspase-9, ↑ caspase-3, ↓ ΔΨm, ↑ apoptosis Likely lower cytotoxicity at food-level exposure R/G Pro-apoptotic tumor-cell killing Core anticancer mechanism across multiple preclinical models; strongest translational signal is apoptosis rather than selective clinical cytotoxicity.
2 PI3K AKT survival signaling ↓ AKT pathway signaling, ↓ proliferation, ↑ apoptosis Not well defined G Survival-pathway suppression Reported in breast, lung, glioma, and other cancer models; pathway centrality is high but clinical validation is absent.
3 STAT3 survival signaling ↓ STAT3 signaling, ↓ proliferation, ↑ apoptosis Not well defined G Anti-proliferative and pro-apoptotic signaling shift Most relevant where STAT3 is constitutively active or coupled to inflammatory survival signaling.
4 NF-κB AP-1 JNK MAPK inflammatory signaling ↓ TNF-induced NF-κB, ↓ AP-1, ↓ JNK, ↓ MAPK kinase signaling ↓ inflammatory signaling may be cytoprotective or anti-inflammatory P/R Anti-inflammatory survival-axis suppression Mechanistically important for inflammation-linked carcinogenesis, but TNF-apoptosis blockade means the biological direction can be context-dependent.
5 Cell cycle and clonogenic growth ↓ proliferation, ↓ colony formation, ↑ G0/G1 arrest or model-specific arrest Not well defined G Growth suppression Observed in prostate, osteosarcoma, breast, lung, and oral-cancer models; generally requires pharmacologic exposure.
6 Autophagy modulation ↑ autophagy markers in oral-cancer models Not well defined R/G Stress-response remodeling May contribute to cell death or adaptive stress response depending on tumor context and dose.
7 Mitochondrial ROS increase ↑ ROS in osteosarcoma and some apoptosis models At low exposure may show antioxidant behavior R/G Oxidative mitochondrial stress Not uniform across studies; oral-cancer data also report ↓ ROS and ↑ GSH, so ROS should be marked model-dependent rather than universally pro-oxidant.
8 GSH antioxidant buffering ↑ GSH in oral-cancer model, with apoptosis and autophagy Potential antioxidant effect R/G Redox-state modulation May reflect compensatory antioxidant response rather than the primary cytotoxic driver.
9 Chemosensitization to cisplatin ↑ cisplatin cytotoxicity, ↑ apoptosis, ↑ anti-tumor signaling effects Normal-cell protection not established G Adjunct sensitization Promising but preclinical; no dosing or safety framework for oncology combination use.
10 Clinical Translation Constraint In-vitro activity often requires high concentration Food/flavoring exposure is safety-limited G Exposure and safety bottleneck GRAS/flavoring status does not imply anticancer-dose safety; metabolism, hepatotoxicity/genotoxic-metabolite concerns, and estragole contamination in botanicals are key constraints.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr
Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
6396- ANE,  FEO,    Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis
- in-vitro, Pca, PC3
TumCP↓, TumCG↓, TumCMig↓, CSCs↓, ROS↑, MPT↑, Casp3↑, Casp9↑, DNAdam↑, cl‑PARP↑, Bax:Bcl2↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, cMyc↓, P21↑, p27↑, NF-kB↓, eff↑,
6398- ANE,    trans-Anethole Abrogates Cell Proliferation and Induces Apoptosis through the Mitochondrial-Mediated Pathway in Human Osteosarcoma Cells
- in-vitro, OS, MG63
*Inflam↓, *AntiTum↑, TumCCA↓, ROS↑, MMP↓, Casp3↑, Casp9↑, P53↑, Bcl-xL↓, MPT↑,
6399- ANE,    Anethole attenuates lung cancer progression by regulating the proliferation and apoptosis through AKT and STAT3 signaling
- vitro+vivo, NSCLC, A549
TumCP↓, TumCG↓, Apoptosis↑, DNAdam↑, Casp3↑, PI3K↓, Akt↓, STAT3↓, Ki-67↓, cl‑Casp3↑,
6406- ANE,    Anethole induces anti-oral cancer activity by triggering apoptosis, autophagy and oxidative stress and by modulation of multiple signaling pathways
- in-vitro, Oral, Ca9-22
TumCP↓, Apoptosis↑, TumAuto↑, ROS↓, GSH↑, cycD1/CCND1↓, P21↑, P53↑, EMT↓, Casp3↑, PARP1↑, TumMeta↓, MMPs↓, TIMP1↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   ROS↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   MPT↑, 2,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 2,   Bax:Bcl2↑, 1,   Bcl-xL↓, 1,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp9↑, 2,   p27↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   P53↑, 2,   cl‑PARP↑, 1,   PARP1↑, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 2,   P21↑, 2,   TumCCA↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 1,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 2,  

Migration ⓘ

Ki-67↓, 1,   MMPs↓, 1,   TIMP1↑, 1,   TumCMig↓, 1,   TumCP↓, 3,   TumMeta↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

Ki-67↓, 1,  
Total Targets: 38

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 2

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
4 Anethole/trans-Anethole
1 Fennel Oil/Foeniculum vulgare
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:402  Target#:42  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page